Biogen heads into Q4 earnings with MS drug pressure, while Leqembi and Skyclarys' growth could help offset declines ahead of ...
A federal judge in Illinois allowed a class action against Biogen Inc. to advance over the drugmaker’s alleged collusion with pharmacy benefit managers to favor its multiple sclerosis drug Tecfidera ...
Biogen tops Q4 earnings and sales estimates, and shares rise after the company issues an encouraging 2026 adjusted EPS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results